# US 2019/0375822 A1 · Methods of treating hemophilia a

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375822 A1
- Document ID: US20190375822A1
- Status: Published application
- Kind: A1
- Application number: 16/415,893
- Filed: 2019-05-17
- Published: 2019-12-12
- Earliest claimed: 2018-05-18
- Assignees: Bioverativ Therapeutics Inc.
- Applicants: Bioverativ Therapeutics Inc.
- Inventors: Ekta SETH CHHABRA; Alison INNES; Dan RUDIN; Kara RICE; Nancy WONG; Suresh KATRAGADDA
- Web page: https://patentgrep.com/patent/US20190375822A1

## CPC

- A61K 38/37: Factors VIII
- C07K 14/755: Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)}
- A61K 38/36: Blood coagulation or fibrinolysis factors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides a method of treating hemophilia A in a human subject in need thereof comprising administering to the subject a chimeric polypeptide comprising (i) a factor VIII (FVIII) protein and (ii) a von Willebrand factor (VWF) fragment comprising a D′ domain of VWF and a D3 domain of VWF at a dosing interval.

## Claims

### Claim at position 1

1-89. (canceled)

### Claim 90

A method of treating hemophilia A in a human subject comprising administering to the subject in need thereof multiple doses of a chimeric polypeptide at a dosing interval, wherein the chimeric polypeptide comprises:
(i) a FVIII protein comprising the amino acid sequence of SEQ ID NO: 203; and
(ii) a VWF protein comprising the amino acid sequence of SEQ ID NO: 205;
wherein at least one of the multiple doses is from 15 IU/kg to 100 IU/kg and the dosing interval is at least 5 days.

### Claim 91 (depends on 90)

The method of claim 90, wherein the multiple doses are 50 IU/kg, and the dosing interval is at least 7 days.

### Claim 92 (depends on 90)

The method of claim 90, wherein the treatment of hemophilia A comprises controlling or decreasing the incidence or frequency of a bleeding episode in a human subject in need thereof.

### Claim 93 (depends on 90)

The method of claim 90, wherein the treatment of hemophilia A comprises preventing or treating a bleeding episode in a human subject in need thereof.

### Claim 94 (depends on 90)

The method of claim 90, wherein at least one of the multiple doses is 25 IU/kg.

### Claim 95 (depends on 90)

The method of claim 90, wherein at least one of the multiple doses is 50 IU/kg.

### Claim 96 (depends on 90)

The method of claim 90, wherein at least one of the multiple doses is 65 IU/kg.

### Claim 97 (depends on 90)

The method of claim 90, wherein the chimeric polypeptide is administered for prophylactic treatment.

### Claim 98 (depends on 90)

The method of claim 90, wherein the chimeric polypeptide is administered intravenously.

### Claim 99 (depends on 90)

The method of claim 90, wherein administration of the chimeric polypeptide results in a FVIII plasma activity level in the subject of at least 1%.

### Claim 100 (depends on 90)

The method of claim 90, wherein administration of the chimeric polypeptide results in a FVIII plasma activity level in the subject of at least 5%.

### Claim 101 (depends on 90)

The method of claim 90, wherein administration of the chimeric polypeptide results in a FVIII plasma activity level in the subject of at least 5% at 5 days after administration.

### Claim 102 (depends on 90)

The method of claim 90, wherein the administration of the chimeric polypeptide induces no FVIII inhibitor after 28 days of the administration.

### Claim 103 (depends on 90)

The method of claim 90, wherein the administration induces immune tolerance to FVIII in the human subject.

### Claim 104 (depends on 90)

The method of claim 90, wherein the administration reduces an inhibitory immune response to FVIII in the human subject.

### Claim 105

A method of treating hemophilia A in a human subject comprising administering to the subject in need thereof multiple doses of a chimeric polypeptide at a dosing interval, wherein the chimeric polypeptide comprises:
(i) a FVIII protein comprising:
(a) a first FVIII polypeptide fragment comprising the amino acid sequence of SEQ ID NO: 215;
(b) a first XTEN sequence comprising the amino acid sequence of SEQ ID NO: 8 (AE288);
(c) a second FVIII polypeptide fragment comprising the amino acid sequence of SEQ ID NO: 216; and
(d) a first Fc region comprising the amino acid sequence of SEQ ID NO: 217;
(ii) a VWF protein comprising:
(a) a D′ domain of VWF comprising the amino acid sequence of SEQ ID NO: 210;
(b) a D3 domain of VWF comprising the amino acid sequence of SEQ ID NO: 214;
(c) a second XTEN sequence comprising the amino acid sequence of SEQ ID NO: 58 (AE144_5A);
(d) an a2 linker comprising the amino acid sequence of SEQ ID NO: 88; and
(e) a second Fc region comprising the amino acid sequence of SEQ ID NO: 217;
wherein the first Fc region is covalently linked to the second Fc region by a disulfide bond.

### Claim 106 (depends on 105)

The method of claim 105, wherein the FVIII protein further comprises a FVIII signal peptide comprising the amino acid sequence of SEQ ID NO: 64.

### Claim 107 (depends on 105)

The method of claim 105, wherein the VWF protein further comprises:
a VWF signal peptide comprising the amino acid sequence of SEQ ID NO: 208; and
a D1D2 domain of VWF comprising the amino acid sequence of SEQ ID NO: 209.

### Claim 108 (depends on 105)

The method of claim 105, wherein at least one of the multiple doses is from 15 IU/kg to 100 IU/kg and the dosing interval is at least 5 days.

### Claim 109 (depends on 105)

The method of claim 105, wherein the multiple doses are 50 IU/kg, and the dosing interval is at least 7 days.
